RYAH
Group,
Inc
Publishes
Report
on
Medical
Cannabis
Use
for
Pain
TORONTO, June
10, 2021 -- InvestorsHub NewsWire -- RYAH Group, Inc.
(CSE:RYAH) ("RYAH" or the "Company") is pleased to announce that its
wholly owned subsidiary, RYAH Medtech Inc. ("RYAH Medtech"), has
published a
data report on use of
medical cannabis
among patients with pain conditions. The data report features
insights into the use of cannabis to treat pain conditions
by patients within the RYAH
Data ecosystem and whether cannabis may be one of the alternative
treatment solutions to reduce opioid use- related problems associated
with existing treatment options. The publication is based on user
feedback provided by more than 40,000 patients that have reported to the RYAH Data ecosystem.
The
report
provides
a
breakdown
based
on
patient
gender,
main
conditions
related
to
pain
management
and
corresponding
strain
types
and
reveals that
pain is one of the top three conditions for medical cannabis
treatment within the RYAH Data ecosystem and also seems to
be one of
the most interesting symptoms for researchers. As of the date
hereof, one of the world's largest clinical trials in cannabis is
focused specifically on pain
management, and further to RYAH's recent
press release, the RYAH Smart Dry-Herb
Inhaler has been selected as the device for such study (with
RYAH Medtech recently having completed its initial shipment of RYAH
Smart Dry Herb Inhalers and RYAH Cartridges
to
the
U.K.
clinic
conducting
the
study).
"The RYAH data
report on cannabis use for pain management comes at a turning point
as studies on alternatives to opioids in treatment
and
potential
efficacy
of
chronic
pain
start
to
accelerate,"
says
Gregory
Wagner,
CEO
of
RYAH.
"The
opioid
crisis,
which
began
with
initially
good intentions
to more effectively treat pain, created a flood of opioids being
prescribed, up from an estimated
70 million prescriptions in the 1990s to more
than
255 million by 2012. RYAH is committed to
providing the tools needed to effectively monitor and measure
dosing in plant-based medicine
treatments and to providing data analytics in order for the
industry to make more informed decisions around alternative
treatments
to
opioids."
About
RYAH
Group,
Inc.
RYAH Group, Inc.
("RYAH") is a connected device and big data and technology company
focused on valuable predictive analysis in the global medical plant and
nutraceutical intake industry. Its robust artificial intelligence
platform aggregates and correlates HIPAA-compliant
patient data,
which is intended to help doctors and patients personalize
plant-based treatments to better predict treatment outcomes.
The data
collection is relevant for clinics, doctors, dispensaries and
pharmaceutical companies and licensed processors (LPs) to monitor
and manage formulation effects
on patients and demographics. With a strong IP portfolio, RYAH
gathers deep and insightful data on the complete patient session and formulation
life
cycle.
Forward-Looking Statements
Certain
statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian
securities
legislation.
The words
"may,"
"would,"
"could,"
"should,"
"potential,"
"will,"
"seek,"
"intend,"
"plan,"
"anticipate,"
"believe,"
"estimate,"
"expect"
and similar expressions as they relate to the Company are intended
to identify forward-looking information. All statements
other than
statements of historical fact may be forward-looking information.
Forward-looking statements in this news release include
statements relating
to
(i)
cannabis
as
a
possible
alternative
treatment
option
for
various
pain
conditions;
(ii)
the
previously
announced
study
undertaken
by the
U.K. clinic on the safety and efficacy of cannabis and hemp for the
treatment of patients suffering from chronic pain; and (ii) the
size of the
medicinal cannabis market. Readers are further cautioned that the
assumptions used in the preparation of such forward-looking
statements,
including,
but
not
limited
to,
the
assumption
that
(i)
the
Company's
financial
condition
and
development
plans
do
not
change
as
a result
of unforeseen events; (ii) there will continue to be a demand and
market opportunity for the Company and its subsidiaries'
product offerings
and/or for cannabis as a potential alternative treatment option for
various pain conditions; (iii) current and future economic
conditions
will neither affect the business and operations of the Company nor
its ability to capitalize on anticipated business
opportunities; and (iv)
the previously announced study undertaken by the U.K. clinic has
the potential to lead to results beneficial to the Company's
business,
although considered reasonable by management of the Company at the
time of preparation, may prove to be imprecise and
result in
actual results differing materially from those anticipated, and, as
such, readers are cautioned not to place undue reliance on
forward-looking
statements.
Forward-looking
information reflects the Company's current views and intentions
with respect to future events and current information
available
to the Company and is subject to certain risks, uncertainties and
assumptions. Many factors could cause the actual results,
performance
or achievements that may be expressed or implied by such
forward-looking information to vary from those described
herein should
one or more of these risks or uncertainties materialize. These
risks include, without limitation, risks associated with or
inherent in (i) the
general business and economic conditions in the regions in which
the Company operates; (ii) the ability of the Company and
its subsidiaries
to execute on key priorities (including completion of acquisitions
and strategic plans and the retention of key executives);
(iii) the
ability of the Company to integrate newly acquired businesses; (iv)
the expected benefits of RYAH's user-generated,
HIPAA-compliant data and
the anticipated results and experience users may receive from using
RYAH products; (v) the Company's ability to implement
business
strategies
and
pursue
business
opportunities;
(vi)
disruptions
in
or
attacks
on
(including
cyber-attacks)
the
Company's
information
technology, internet, network access or other voice or data
communications systems or services; (vii) the evolution of
various types
of
fraud
or
other
criminal
behavior
to
which
the
Company
is
exposed;
(viii)
the
failure
of
third
parties
to
comply
with
their
obligations
to
the
Company or its affiliates; (ix) changes to, or the application of,
laws and regulations, legal and regulatory risks inherent in the
cannabis industry;
and (x) cannabis-related products manufactured for human
consumption (including potential product recalls). Should any
such factor
affect the Company in an unexpected manner, or should assumptions
underlying the forward-looking information prove incorrect,
the actual
results or events may differ materially from the results or events
predicted. The forward-looking information included in this
press release
is made as of the date of this press release and is expressly
qualified in its entirety by this cautionary statement. The
Company undertakes
no
obligation
to
publicly
update
or
revise
any
forward-looking
information,
other
than
as
required
by
applicable
law.
This
press release includes market and industry data that has been
obtained from third-party sources, including industry publications.
The Company
believes that the industry data is accurate and that its estimates
and assumptions are reasonable, but there is no assurance as
to the
accuracy or completeness of this data. Third-party sources
generally state that the information contained therein has been
obtained from
sources believed to be reliable, but there is no assurance as to
the accuracy or completeness of included information. Although
the data is
believed to be reliable, the Company has not independently verified
any of the data from third-party sources referred to in this
press release
or
ascertained
the
underlying
economic
assumptions
relied
upon
by
such
sources.
RYAH
Medtech
Inc
Contacts:
Sofiya
Kleshchuk
Client
Relations
+1
917
210
0543
Invest@ryahgroup.com
Gregory
Wagner,
CEO
917
210
0543
Info@ryah.com
Corporate
Communications:
InvestorBrandNetwork
(IBN)
Los Angeles,
California www.InvestorBrandNetwork.com
310.299.1717
Office
Editor@InvestorBrandNetwork.com